Professor

current position:

Home - Investigator - Professor

WANG Zhen

Source:

time:2021-11-30

Views:


NameWANG Zhen

DepartmentBiochemistry Department

Tel: (8610)63165289

Email: wangzhen@imb.pumc.edu.cn

Education & Research Experience

A. Educational Background

B.S. - Clinical Medicine, Shan Dong Medical College, China, 1997

Ph.D.-Microbial and Biochemical Pharmaceutics, Peking Union Medical College, 2002

B. Academic Positions and Professional Employment

2011-present

Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, PUMC & CAMS, China

2005-2011

Associate Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, PUMC & CAMS, China

2002-2005

Assistant Professor, Department of Biochemistry, Institute of Medicinal Biotechnology, Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), China

2002-2004

Postdoctoral fellow, Department of Cancer Biology and Pharmacology, Genome Institute of Singapore, Singapore

2006-2008

Postdoctoral fellow, Department of Radiation Oncology, University of Michigan, Ann Arbor, USA

Research Field

Molecular mechanisms underlying cancer and bone diseases, and drug discovery, development and treatment for the diseases

Research Interests

We are interested in understanding the role and acting mechanisms of a panel of E3 ubiquitin ligases in cancer and bone diseases, and aim to find out potential drug target for new drug discovery and development to treat these diseases.

Selected publications

1. Zhao X, Lin S, Li H, Si S*, Wang Z*. Myeloperoxidase controls bone turnover by suppressing osteoclast differentiation through modulating reactive oxygen species level. J Bone Mineral Res. 2021, 36(3):591-603.

2. Lin S, Zhao X, Wang Z*. TANK-binding kinase 1 mediates osteoclast differentiation by regulating NF-kB, MAPK and Akt signaling pathways. Immunology & Cell Biology. 2021, 99(2):223-233.

3. Shen J, Zhan Y, Li H and Wang Z*, Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines. Acta Pharmacologica Sinica. 2019, i0:1-9.

4. Shen J, Li P, Shao X, Yang Y, Liu XJ, Feng M, Yu Q, Hu R*, Wang Z*. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival. Cancer Research. 2018;78(2):359-371.

5. Sha MQ, Zhao XL, Li L, Li LH, Li Y, Dong TG, Niu WX, Jia LJ, Shao RG, Zhen YS, Wang Z*. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells. Cell Death Dis. 2016, 24;7(11):e2486.

6. Sha M, Mao G, Wang G, Chen Y, Wu X, Wang Z*. DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharmaceutica Sinica B. 2015; 5(3):188-193.

7. Wang Y, Zhan Y, Xu R, Shao R, Jiang J*, Wang Z*. Src mediates extracellular signal-regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non-small cell lung cancer cell lines. Molecular Carcinogenesis. 2015;54 Suppl 1:E26-34.

8. Ji X, Xue S, Zhan Y, Shen J, Wu L, Jin J, Wang Z*, Li Z*. Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives. European Journal of Medicinal Chemistry. 2014, 83C:409-418.

9. Wang Y, Qiu Q, Shen JJ, Li DD, Jiang Xuejun, Si Suyi, Shao RG, Wang Z*. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. International Journal of Biochemistry & Cell Biology. 2012, 44:1813-1824.

10. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP, Zheng W, Xie Z, Sun Y*. Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research. 2009, 69(16): 6556-6564.

Awards and Honors

2013, CHPHARS-SERVIER Young Investigator Award in Pharmacology, Chinese Pharmacological Society;

2009, CPA-Sanofi-Aventis Young Investigator Award in Biological drugs, Chinese Pharmaceutical Association;

2005, Beijing Science and Technology Award;

2004, New Star of Science and Technology, Beijing, China

Academic Appointments

2013-present, Member of Committee of Anti-Cancer Agent, Chinese Anti-cancer Association;

2018-present, Member of youth Committee of Chinese Anti-cancer Association;

2009-present, Member of Aging and Anti-aging Association, Gerontological Society of China;

2007-present, Active Member of AACR